Welcome to our dedicated page for QT Imaging Holdings SEC filings (Ticker: QTIH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QT Imaging Holdings, Inc. (QTIH) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports, registration statements, and related exhibits. QT Imaging is a medical device company in the healthcare sector that develops and commercializes body imaging systems using low frequency sound waves, and its filings offer detailed insight into its capital structure, financing arrangements, and operational progress.
Investors can review Form 8-K current reports where QT Imaging discloses material events such as private placement (PIPE) financings, warrant repurchases, amendments to credit agreements, and the implementation of a 3:1 reverse stock split of its common stock. Certain 8-K filings also furnish unaudited pro forma condensed consolidated financial statements, which show how transactions like the September 2025 private placement and subsequent debt repayments affect the company’s balance sheet and statements of operations.
The company has filed a Form S-1 registration statement and an amended Form S-1/A, which contain information about its securities, historical financial statements, and various equity and debt instruments, including warrants, convertible notes, bridge loans, and earnout arrangements. These documents, together with other periodic and transactional filings, outline QT Imaging’s status as an emerging growth company and describe key elements of its financing history and customer concentration.
On Stock Titan, these filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries help explain the significance of complex disclosures, highlighting items such as changes to rights of security holders, reverse stock split mechanics, private placement terms, and pro forma adjustments. Users can quickly locate quarterly and annual financial information within registration statements, track capital markets actions, and examine how QT Imaging reports on its imaging business, cloud platform development, and related risks in its official SEC documents.
Dinu Raluca reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Executive Officer Raluca Dinu received equity awards of common stock as compensation. On March 20, 2026, she was granted 3,500, 500,000, and 16,000 shares of common stock at a price of $0.00 per share under the company’s equity plan.
After these awards, the filing shows she directly owns 908,845 common shares. Footnotes explain these are restricted stock units with vesting schedules running from May 15, 2026 through dates as late as February 15, 2030 or May 15, 2029, with full acceleration upon a qualifying Change of Control.
Dinu Raluca reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. reported that Chief Executive Officer Raluca Dinu received equity awards of common stock as compensation. On March 20, 2026, she was granted 3,500, 500,000, and 16,000 shares of common stock at a price of $0.00 per share under the company’s equity plan.
After these awards, the filing shows she directly owns 908,845 common shares. Footnotes explain these are restricted stock units with vesting schedules running from May 15, 2026 through dates as late as February 15, 2030 or May 15, 2029, with full acceleration upon a qualifying Change of Control.
Katz Avi S reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. chairman Avi S. Katz received a grant of 3,500 shares of common stock on March 20, 2026 as a stock award, at a stated price of $0.00 per share. Following this grant, he directly holds 416,952 common shares.
The award is structured as restricted stock units. Subject to his continued service, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately if the company undergoes a Change of Control under its 2024 Equity Incentive Plan.
Katz Avi S reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings, Inc. chairman Avi S. Katz received a grant of 3,500 shares of common stock on March 20, 2026 as a stock award, at a stated price of $0.00 per share. Following this grant, he directly holds 416,952 common shares.
The award is structured as restricted stock units. Subject to his continued service, 25% of the RSUs will vest on each of May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027. All RSUs will vest immediately if the company undergoes a Change of Control under its 2024 Equity Incentive Plan.
QT Imaging Holdings, Inc. released an investor presentation highlighting rapid commercial growth for its breast imaging platform and updated financials. Revenue reached $18.9 million in 2025, up from $4.9 million in 2024, driven by shipment of 40 QT Breast Acoustic CT scanners under distribution agreements.
Q4 2025 revenue was $8.3 million, an 877% year-over-year increase, with 38% gross margin and a net loss of $1.4 million. Adjusted EBITDA improved to $(0.4) million from $(1.9) million a year earlier. The company ended 2025 with $10.5 million in cash after an oversubscribed $18.2 million private placement and new debt financing, and it expects approximately $39 million of revenue in 2026, including initial SaaS cloud platform contributions.
QT Imaging Holdings, Inc. released an investor presentation highlighting rapid commercial growth for its breast imaging platform and updated financials. Revenue reached $18.9 million in 2025, up from $4.9 million in 2024, driven by shipment of 40 QT Breast Acoustic CT scanners under distribution agreements.
Q4 2025 revenue was $8.3 million, an 877% year-over-year increase, with 38% gross margin and a net loss of $1.4 million. Adjusted EBITDA improved to $(0.4) million from $(1.9) million a year earlier. The company ended 2025 with $10.5 million in cash after an oversubscribed $18.2 million private placement and new debt financing, and it expects approximately $39 million of revenue in 2026, including initial SaaS cloud platform contributions.
QT Imaging Holdings, Inc. reported preliminary unaudited results showing record revenue of $8.3 million in Q4 2025 and $18.9 million for full-year 2025, exceeding its $18 million outlook. Q4 revenue rose 877% year over year and 97% sequentially, driven by shipment of 17 Breast Acoustic CT™ scanners.
For 2025, revenue grew 288% versus 2024, with 40 scanners shipped. Gross margin was 45% for the year and 38% in Q4. Despite this growth, the company recorded a 2025 net loss of $21.1 million, influenced by $8.8 million of other expense tied to term loan issuance, note extinguishments and fair value changes.
Non-GAAP Adjusted EBITDA improved to $(3.5) million from $(7.4) million in 2024, while net cash used in operating activities narrowed to $9.0 million. Cash, restricted cash and equivalents reached $10.5 million at year-end 2025 after an $18.2 million private placement and new debt financings. The company relisted on Nasdaq and is pivoting from pure hardware to a SaaS and biomarker-driven imaging platform, and it projects 2026 revenue of about $39 million, including initial SaaS Cloud Platform contributions.
QT Imaging Holdings, Inc. reported preliminary unaudited results showing record revenue of $8.3 million in Q4 2025 and $18.9 million for full-year 2025, exceeding its $18 million outlook. Q4 revenue rose 877% year over year and 97% sequentially, driven by shipment of 17 Breast Acoustic CT™ scanners.
For 2025, revenue grew 288% versus 2024, with 40 scanners shipped. Gross margin was 45% for the year and 38% in Q4. Despite this growth, the company recorded a 2025 net loss of $21.1 million, influenced by $8.8 million of other expense tied to term loan issuance, note extinguishments and fair value changes.
Non-GAAP Adjusted EBITDA improved to $(3.5) million from $(7.4) million in 2024, while net cash used in operating activities narrowed to $9.0 million. Cash, restricted cash and equivalents reached $10.5 million at year-end 2025 after an $18.2 million private placement and new debt financings. The company relisted on Nasdaq and is pivoting from pure hardware to a SaaS and biomarker-driven imaging platform, and it projects 2026 revenue of about $39 million, including initial SaaS Cloud Platform contributions.
Alyeska Investment Group and related parties reported a sizable position in QT Imaging Holdings, Inc. common stock. As of December 31, 2025, they beneficially owned 1,178,317 shares, representing 9.99% of the company’s common stock.
The position is held through 670,683 common PIPE shares, pre-funded warrants for 440,427 shares, and warrants for 1,111,111 shares. These warrants are subject to a 9.9% beneficial ownership limitation, meaning they can only be exercised to a level where Alyeska would hold up to 9.9% of QT Imaging’s outstanding common stock after exercise.
The ownership figures are based on 11,902,198 shares outstanding, as disclosed in QT Imaging’s prospectus dated December 31, 2025. Alyeska certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Alyeska Investment Group and related parties reported a sizable position in QT Imaging Holdings, Inc. common stock. As of December 31, 2025, they beneficially owned 1,178,317 shares, representing 9.99% of the company’s common stock.
The position is held through 670,683 common PIPE shares, pre-funded warrants for 440,427 shares, and warrants for 1,111,111 shares. These warrants are subject to a 9.9% beneficial ownership limitation, meaning they can only be exercised to a level where Alyeska would hold up to 9.9% of QT Imaging’s outstanding common stock after exercise.
The ownership figures are based on 11,902,198 shares outstanding, as disclosed in QT Imaging’s prospectus dated December 31, 2025. Alyeska certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
QT Imaging Holdings, Inc. received an updated ownership report from investment firm Lynrock Lake entities and Cynthia Paul. As of December 31, 2025, they beneficially owned 1,154,586 shares of QT Imaging common stock, representing 9.7% of the outstanding shares based on 11,902,198 shares reported outstanding.
The shares are directly held by Lynrock Lake Master Fund LP, with voting and investment power delegated to Lynrock Lake LP as investment manager and influenced by Cynthia Paul through her roles at the related entities. Lynrock Lake Master also holds warrants that are currently restricted by approximately 4.9% beneficial ownership limits. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of QT Imaging.
QT Imaging Holdings, Inc. received an updated ownership report from investment firm Lynrock Lake entities and Cynthia Paul. As of December 31, 2025, they beneficially owned 1,154,586 shares of QT Imaging common stock, representing 9.7% of the outstanding shares based on 11,902,198 shares reported outstanding.
The shares are directly held by Lynrock Lake Master Fund LP, with voting and investment power delegated to Lynrock Lake LP as investment manager and influenced by Cynthia Paul through her roles at the related entities. Lynrock Lake Master also holds warrants that are currently restricted by approximately 4.9% beneficial ownership limits. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of QT Imaging.
QT Imaging Holdings, Inc. updates its S-1 covering 29,336,017 shares of common stock by incorporating three recent developments. The company signed an exclusive distribution agreement with Al Naghi Medical Co. to market and sell its breast imaging scanners and cloud platform in the United Arab Emirates through January 19, 2029, subject to minimum purchase requirements. It completed a January 2026 private placement with its board chairman, issuing 24,107 shares at $6.43 plus a 10‑year warrant for up to 48,214 additional shares, raising about $155,002 for working capital and granting registration rights. Pro forma information also reflects an earlier October 2025 private placement of about $18.18 million and repayment of about $5.36 million of debt and related amounts. In addition, Nasdaq approved the company’s common stock for listing on the Nasdaq Capital Market under the symbol “QTI”, with trading expected to begin on January 28, 2026.
QT Imaging Holdings, Inc. reports that Nasdaq has approved the listing of its common stock on the Nasdaq Capital Market. The shares are expected to begin trading under the ticker symbol “QTI” on January 28, 2026, moving from a prior trading venue not described here.
The company highlights that this uplisting remains subject to meeting Nasdaq’s ongoing listing standards and pairs the news with an extensive caution about forward-looking statements. It notes risks around successfully commercializing its QT Imaging Breast Acoustic CT™ Scanner, expanding product offerings, securing financing, addressing a material weakness in internal controls, and meeting business milestones. A press release announcing the uplisting is filed as Exhibit 99.1.
QT Imaging Holdings chairman Avi Katz reported new purchases of company securities. On January 22, 2026, he bought 24,107 shares of common stock at $6.43 per share, bringing his directly held common stock to 413,452 shares, adjusted for a 3-for-1 reverse stock split effected on October 23, 2025.
On the same date, he also purchased 48,214 private warrants with a $6.43 exercise price. Each warrant is exercisable for one share of common stock starting July 22, 2026 and expiring on July 22, 2036. Following these transactions, he directly holds 48,214 private warrants in addition to his common shares.